Pace® Life Sciences - Comprehensive Analysis Report
Summary
Pace® Life Sciences is a leading contract research, development, and manufacturing organization (CRDMO) and a full-service FDA-registered GMP analytical testing laboratory. Its core mission is to advance science, contributing to a safer and healthier world through comprehensive contract services for the pharmaceutical, biopharmaceutical, and gene therapy industries. The company plays a significant role in the entire drug development process, offering support from early-phase research and development through clinical trials and Good Manufacturing Practice (GMP) commercial product support, establishing itself as a vital partner in bringing life-saving therapies to market.
1. Strategic Focus & Objectives
Core Objectives
Pace® Life Sciences' primary objective is to efficiently advance client programs from preclinical stages through clinical development to commercialization. This involves providing a full suite of integrated services, including CMC (Chemistry, Manufacturing, and Controls) development, clinical trial materials (CTM) manufacturing, regulatory compliance, and consulting. A key focus is accelerating the delivery of medicines into clinical settings.
Specialization Areas
The company specializes in early-phase development services such such as lyophilization and spray-drying process development, phase-appropriate analytical development, test article preparation, and CTM manufacturing and packaging. They also offer IND-enabling services, comprehensive characterization of small molecules, biologics (proteins, peptides, antibodies, antibody-drug conjugates), and gene therapies (e.g., oligonucleotides). Pace® Life Sciences is actively expanding its sterile fill-finish capabilities, particularly for clinical trial manufacturing, and increasing its biopharmaceutical analytical services, leveraging state-of-the-art facilities and experienced industry experts.
Target Markets
Pace® Life Sciences primarily targets the pharmaceutical, biopharmaceutical, and gene therapy industries. Their market positioning emphasizes providing integrated, end-to-end solutions across the entire drug development lifecycle, supported by a network of U.S.-based CDMO sites, GMP analytical testing laboratories, and manufacturing support service centers.
2. Financial Overview
Funding History
Pace® is a portfolio company of Leonard Green & Partners and Los Angeles-based Aurora Capital Partners. The company's growth strategy is significantly backed by private equity investment, which supports both organic initiatives and strategic acquisitions. Pace Analytical Life Sciences has an estimated annual revenue of $104.5 million. Continued growth is anticipated through these investments and an active acquisition strategy.
3. Product Pipeline
As a contract research, development, and manufacturing organization (CRDMO), Pace® Life Sciences supports the pipeline development of its pharmaceutical, biopharmaceutical, and gene therapy clients rather than having its own proprietary drug pipeline. Their services are crucial for advancing therapies through preclinical and clinical stages. Offerings include preformulation and formulation development, bioavailability enhancement, and clinical supplies manufacturing for sterile products, tablets, capsules, solutions, suspensions, and semi-solids. They also provide analytical development and method validation, solid-state API characterization, nitrosamine risk assessment, extractables/leachables testing, and stability storage and testing. Recent investments in enhanced sterile fill-finish capabilities, including an isolated vial filling line for aseptic processing at their Salem, NH facility, are specifically designed to meet the rising demand for injectables, such as vaccines, gene therapies, antibodies, and protein-based therapeutics.
4. Technology & Innovation
Technology Stack
Pace® Life Sciences leverages state-of-the-art facilities, equipment, and technology, continuously researching and adopting new methodologies to ensure quality in processes, results, and data.
Proprietary Technologies/Specialty Technologies: The company incorporates specialty pharmaceutical manufacturing technologies such as nanomilling, hot melt extrusion, spray drying, and liquid-filled capsules to address complex drug product challenges and ensure potency and quality. They utilize a Design of Experiments (DOE) approach to assess samples under accelerated stress conditions and select stable formulations with sufficient solubility.
Significant Scientific Methods: They perform advanced analytical characterization of biologics and solid-state API characterization. Bioanalytical services support lead selection and optimization with robust assays for regulatory submissions. Their microbiology testing adheres to USP/NF, EP, and JP standards. They also conduct nitrosamine risk assessment and extractables/leachables testing. Their facilities include dedicated RNase-free environments and offer extensive cell-based assay support.
Innovation: Pace® Life Sciences demonstrates a commitment to innovation through continuous improvement processes, adopted from Lean and Six Sigma principles. They actively invest in expanding capabilities, such as the enhanced cGMP manufacturing capabilities for sterile injectables at their Salem, NH facility, which includes an isolated vial filling line offering high sterility assurance and EU Annex 1 compliance.
5. Leadership & Management
Executive Team
Ken Beyer: Chief Executive Officer (Pace® Analytical). Appointed December 5, 2025. He brings over 25 years of executive experience in logistics, technology, and global operations.
Dawn Von Rohr: President, Pace® Life Sciences. She emphasizes the company's commitment to partners and accelerating the delivery of medicines into clinical settings. LinkedIn profile: https://www.linkedin.com/in/dawn-von-rohr-20b8b17
Frank Tagliaferri, Ph.D.: Chief Science Officer, Pace® Life Sciences. He plays a key role in advancing clinical trial materials development and has contributed to discussions on advancing oral drug delivery and cGMP manufacturing in the injectable space. LinkedIn profile: https://www.linkedin.com/in/frank-tagliaferri-aa317215
Dean Bornilla: Head of Commercial, Pace® Life Sciences. Appointed July 23, 2024. He leads commercial growth teams and brings over 25 years of pharmaceutical expertise. LinkedIn profile: https://www.linkedin.com/in/dean-bornilla-0210343
Lou Forcellini: Head of Quality Assurance, Pace® Life Sciences. He has highlighted the company's dedication to data integrity, compliance, and robust quality systems following positive FDA inspections.
Judy Morgan: Chief Compliance Officer, Pace® Analytical. She oversees the company's sustainability initiatives and compliance. LinkedIn profile: https://www.linkedin.com/in/judy-morgan-89142b6
Greg Whitman: President, Pace® Analytical Services. He focuses on continuous improvement for client and employee value. LinkedIn profile: https://www.linkedin.com/in/gregwhitman
Recent
Leadership ChangesKen Beyer was appointed Chief Executive Officer of Pace® on December 5, 2025, succeeding Eric Roman. Dean Bornilla was named Head of Commercial for Pace® Life Sciences on July 23, 2024, reporting to President Dawn Von Rohr. Gregory D. Kupp previously held the role of President of Pace® Life Sciences. These changes reflect a strategic effort to bring in experienced leadership to drive continued growth and commercial expansion.
6. Talent and Growth Indicators
Pace® Life Sciences is in a period of significant growth, employing approximately 520 individuals and reporting an 8% growth in employee count last year. The broader Pace® organization has a total of 2,890 employees. The company is actively recruiting for various roles, including Project Coordinator, Analytical Chemist, Associate Scientist, QA Specialist (GMP Pharma), Client Project Manager, and Sales Account Executive, among others. Significant expansion efforts, such as doubling biopharmaceutical analytical services at its Oakdale, MN facility and enhancing sterile fill-finish capabilities at Salem, NH, are creating new job opportunities. The expansion of the Oakdale, MN campus is expected to create over 50 new jobs. Acquisitions in 2024, including research Triangle Park, NC, and Lebanon, NJ locations, have expanded the company's network to 9 sites, further indicating robust growth and the need for talent acquisition guided by its "People Advancing Science®" ethos.
7. Social Media Presence and Engagement
Pace® Life Sciences maintains an active social media presence across platforms such as LinkedIn, Twitter, and YouTube. The company uses these channels to share news, industry insights, and thought leadership, including webinars on critical industry topics. They promote their commitment to advancing science and improving health, highlight new capabilities like sterile fill-finish manufacturing expansion, announce regulatory successes such as positive FDA inspections, and showcase sustainability initiatives. The "Keeping Pace® with Pharma" blog serves as a platform for disseminating the latest news and expert perspectives.
Twitter (Pace Analytical Services): https://twitter.com/KenBeyer (CEO Ken Beyer)
LinkedIn (Pace® Life Sciences): https://www.linkedin.com/company/pacelifesciences/
LinkedIn (Dawn Von Rohr): https://www.linkedin.com/in/dawn-von-rohr-20b8b17
LinkedIn (Frank Tagliaferri, Ph.D.): https://www.linkedin.com/in/frank-tagliaferri-aa317215
LinkedIn (Dean Bornilla): https://www.linkedin.com/in/dean-bornilla-0210343
LinkedIn (Judy Morgan): https://www.linkedin.com/in/judy-morgan-89142b6
LinkedIn (Greg Whitman): https://www.linkedin.com/in/gregwhitman
LinkedIn (Gregory D. Kupp): https://www.linkedin.com/in/gregory-d-kupp-b52b274
8.
Recognition and AwardsPace® Life Sciences has received notable recognition for its industry contributions and operational practices. It has been recognized by PharmaSource as a Top CDMO in the United States, acknowledging its comprehensive solutions, strong regulatory track record, and customer-focused approach. The company has also achieved multiple consecutive positive FDA inspections at its various facilities, reinforcing its commitment to quality and compliance.
9. Competitive Analysis
Major Competitors
Pace® Life Sciences operates within the highly competitive contract development and manufacturing (CDMO) and contract research organization (CRO) markets. Key competitors offering comprehensive services to the pharmaceutical, biopharmaceutical, and gene therapy industries include:
Lonza: A global CDMO and CMO with extensive capabilities across small molecules, biologics, and cell and gene therapies, providing integrated solutions from discovery to commercialization. Lonza is known for its broad portfolio and global presence.
Thermo Fisher Scientific Inc. (including PPD): A major scientific services provider that has significantly expanded its CDMO/CRO capabilities through acquisitions. They offer end-to-end drug development, delivery, and manufacturing solutions with global reach and diverse technological expertise.
Catalent, Inc.: A global CDMO specializing in drug development, delivery, and manufacturing, with broad operations worldwide. While Pace® Life Sciences acquired a Catalent facility, Catalent remains a significant competitor in the broader CDMO space.
WuXi Biologics: A global CRDMO providing end-to-end solutions for biologics, from discovery to commercial manufacturing, known for its extensive capacity and integrated service offerings for large molecules.
ICON: A global CRO that manages complex clinical trials, possessing extensive therapeutic expertise and offering a wide range of clinical development services.
IQVIA: A leading global provider that integrates data analytics, technology solutions, and clinical research services across the life sciences industry, offering a unique blend of CRO services and market intelligence.
Parexel: A large, global CRO offering a full range of Phase I to IV clinical development services, renowned for its regulatory expertise and clinical trial management capabilities.
These competitors, similar to Pace® Life Sciences, emphasize comprehensive service offerings, technological innovation, and stringent regulatory compliance to attract clients in the life sciences sector.
10. Market Analysis
Market Overview
The market for pharmaceutical, biopharmaceutical, and gene therapy development and manufacturing services is experiencing robust growth. This demand is fueled by the increasing number of complex biologics, gene therapy products, and precision medicines entering development, particularly those requiring parenteral administration. The global cell and gene therapy CDMO market size was estimated at USD 10.35 billion in 2025 and is projected to reach approximately USD 125.09 billion by 2035, growing at a CAGR of 28.3%. Another estimate places the cell and gene therapy CDMO market at USD 4.31 billion in 2026, projected to reach USD 9.08 billion by 2031 with a 16.08% CAGR. North America holds a significant share of this market, accounting for 41% in 2025.
Key drivers include the increasing demand for outsourced research and manufacturing services, a focus on addressing unmet medical needs, advancements in manufacturing technologies (like sterile fill-finish and viral vectors), and substantial R&D investments by pharmaceutical companies. The oncology segment dominated the cell and gene therapy CDMO market in 2025, holding a 50.0% revenue share, while the pre-clinical segment held the largest revenue share of 69% in 2025. The biopharmaceutical contract manufacturing market, valued at USD 22.40 billion in 2025, is projected to grow at a CAGR of 8.8% during the forecast period due to the rising demand for biologics and personalized medicine. Companies that can offer integrated, end-to-end solutions and adapt to evolving regulatory landscapes, such as stringent GMP compliance and EU Annex 1 for sterile manufacturing, are well-positioned for success.
11. Strategic Partnerships
Pace® Life Sciences actively pursues strategic partnerships primarily through an aggressive acquisition strategy and strong client relationships. These collaborations aim to expand capabilities, geographic reach, and service offerings.
Velesco Pharmaceutical Services (October 2021): Acquisition that added expertise in liquid, semi-solid, and oral solid dose product development.
Meridian BioGroup (August 2022): Acquisition that expanded regulatory, compliance, and validation capabilities.
Biopharma Global (September 2022): Acquisition that enhanced FDA regulatory affairs strategy and consulting, particularly for orphan and non-orphan products with unmet medical needs.
*Catal
